JP2023515668A5 - - Google Patents

Info

Publication number
JP2023515668A5
JP2023515668A5 JP2022552546A JP2022552546A JP2023515668A5 JP 2023515668 A5 JP2023515668 A5 JP 2023515668A5 JP 2022552546 A JP2022552546 A JP 2022552546A JP 2022552546 A JP2022552546 A JP 2022552546A JP 2023515668 A5 JP2023515668 A5 JP 2023515668A5
Authority
JP
Japan
Prior art keywords
compound
composition according
pharmaceutically acceptable
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552546A
Other languages
English (en)
Japanese (ja)
Other versions
JP7776430B2 (ja
JP2023515668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/021037 external-priority patent/WO2021178768A1/en
Publication of JP2023515668A publication Critical patent/JP2023515668A/ja
Publication of JP2023515668A5 publication Critical patent/JP2023515668A5/ja
Priority to JP2025194189A priority Critical patent/JP2026015489A/ja
Application granted granted Critical
Publication of JP7776430B2 publication Critical patent/JP7776430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552546A 2020-03-06 2021-03-05 Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法 Active JP7776430B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025194189A JP2026015489A (ja) 2020-03-06 2025-11-13 Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986096P 2020-03-06 2020-03-06
US62/986,096 2020-03-06
PCT/US2021/021037 WO2021178768A1 (en) 2020-03-06 2021-03-05 Methods of treating apol-1 dependent focal segmental glomerulosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025194189A Division JP2026015489A (ja) 2020-03-06 2025-11-13 Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法

Publications (3)

Publication Number Publication Date
JP2023515668A JP2023515668A (ja) 2023-04-13
JP2023515668A5 true JP2023515668A5 (https=) 2024-03-05
JP7776430B2 JP7776430B2 (ja) 2025-11-26

Family

ID=75223507

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552546A Active JP7776430B2 (ja) 2020-03-06 2021-03-05 Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法
JP2025194189A Pending JP2026015489A (ja) 2020-03-06 2025-11-13 Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025194189A Pending JP2026015489A (ja) 2020-03-06 2025-11-13 Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法

Country Status (12)

Country Link
US (2) US11801234B2 (https=)
EP (1) EP4114385A1 (https=)
JP (2) JP7776430B2 (https=)
KR (1) KR20220151634A (https=)
CN (1) CN115209894B (https=)
AU (1) AU2021230562A1 (https=)
BR (1) BR112022017189A2 (https=)
CA (1) CA3173808A1 (https=)
IL (1) IL296035A (https=)
MX (1) MX2022010748A (https=)
TW (1) TWI865738B (https=)
WO (1) WO2021178768A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
ES2363941T3 (es) 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
BRPI0507657A (pt) 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE602005009745D1 (de) 2004-12-16 2008-10-23 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
WO2007025943A2 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2006289093A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
WO2008049923A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
CA2668623A1 (en) 2006-11-06 2008-05-15 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2007316613B2 (en) 2006-11-09 2013-11-28 Boehringer Ingelheim International Gmbh Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
DK2178870T3 (en) 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
US10130632B2 (en) * 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
CN104007258B (zh) * 2013-09-30 2016-07-06 中国医学科学院基础医学研究所 局灶性节段性肾小球硬化的蛋白标志物
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
HUE053705T2 (hu) 2015-08-27 2021-07-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
CN106539843A (zh) * 2017-01-11 2017-03-29 刘国勇 山竹在制备治疗局灶节段性肾小球硬化药物方面的新用途
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
US11618746B2 (en) * 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
JP2023524563A (ja) 2020-05-07 2023-06-12 ラムバム メド－テック リミテッド Ａｐｏｌ１－関連疾患の治療に使用するための組成物
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN115867532A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same

Similar Documents

Publication Publication Date Title
JP2023515668A5 (https=)
TWI595873B (zh) 用於治療中樞誘發噁心及嘔吐之組成物及方法
EP3038654B1 (en) New use
ES2259289T3 (es) Formulacion de benzamida con actividad inhibidora de la histona desacetilasa.
KR102319078B1 (ko) 궤양성 대장염의 치료용 의약 조성물
JP2023116489A5 (https=)
JP2022548687A5 (https=)
CN105050624A (zh) 利用阿普斯特来治疗银屑病关节炎的方法
US20160158202A1 (en) Low Dose Pharmaceutical Composition
CN1461218A (zh) 阿洛地平和贝那普利的治疗组合
JP2022500485A5 (https=)
JP2023528896A5 (https=)
WO2010006103A1 (en) Method for enhancing cognition or inhibiting cognitive decline
TWI674907B (zh) 包括ＨＭＧ-ＣｏＡ還原酶抑制劑及鈣通道阻斷劑之組合製劑
MX2008006550A (es) Metodos y composiciones para el tratamiento de trastornos gastrointestinales.
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
US7625940B2 (en) Method of treating hypertension with a very low dose of chlorthalidone
JP2024505515A5 (https=)
CN100453081C (zh) 用于治疗糖尿病性肾病的吡啶基亚磺酰氨基嘧啶
JP2022550458A5 (https=)
KR20060130619A (ko) 유기 화합물의 조합물
CN109589325B (zh) 一种用于治疗肠炎的药物组合物及其制备方法
CA2823655A1 (en) Methods for treating prostatitis
JP2009511535A (ja) ５−（２−クロロフェニル）−１，２−ジヒドロ−７−フルオロ−８−メトキシ−３−メチル−ピラゾロ［３，４−ｂ］［１，４］ベンゾジアゼピン
US11648252B2 (en) Methotrexate for use as a medicament